Regulation of DNA Methylation in Rheumatoid Arthritis Synoviocytes

Kazuhisu Nakano, David L. Boyle and Gary S. Firestein

*J Immunol* 2013; 190:1297-1303; Prepublished online 31 December 2012;
doi: 10.4049/jimmunol.1202572
http://www.jimmunol.org/content/190/3/1297

Why *The JI*?

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

References  This article cites 42 articles, 4 of which you can access for free at:
http://www.jimmunol.org/content/190/3/1297.full#ref-list-1

Subscription  Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions  Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts  Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

The *Journal of Immunology* is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
Regulation of DNA Methylation in Rheumatoid Arthritis Synoviocytes

Kazuhisa Nakano,*† David L. Boyle,* and Gary S. Firestein*

Rheumatoid arthritis (RA) is an immune-mediated disease marked by synovial inflammation and joint damage. Pre-determined risk factors, such as genetics, play major role in the development of RA. For instance, genome-wide association studies demonstrate numerous polymorphisms associated with RA susceptibility. Genetics does not fully explain the risk of developing RA, as identical twins have a concordance rate of 12–15% (1, 2). Stochastic factors, such as environmental exposures and epigenetic changes, could account for the nongenetic components of disease susceptibility.

Differential DNA methylation at CpG is a well-characterized epigenetic hallmark for several diseases, most notably cancer (3). More recently, altered DNA methylation has been observed in autoimmune diseases like RA and systemic lupus erythematosus (4–6). CpG methylation is established and maintained by DNA methyltransferases (DNMTs), which transfer a methyl group from S-adenosylmethionine to cytosine (7). Three mammalian DNMTs have been described: DNMT1 maintains the existing methylation patterns during DNA replication, whereas DNMT3a and DNMT3b are responsible for de novo CpG methylation (8).

Fibroblast-like synoviocytes (FLS) in the synovial intimal lining play an integral role in RA by producing key cytokines, small-molecule mediators, and proteases (9). Rheumatoid FLS exhibit an aggressive phenotype that could contribute to the inflammatory milieu and damage to the extracellular matrix (10, 11). Several mechanisms that potentially contribute to the rheumatoid phenotype have been proposed, including abnormal tumor suppressor gene function (12), sentrin (13), PTEN (14), or sumoylation. Differential DNA methylation could also alter gene expression and synoviocyte function, and DNA methylation abnormalities have been described (15–17). Our array-based DNA methylation analysis recently revealed a rheumatoid DNA methylome signature involving genes that are critical to cell trafficking, inflammation, and cell–extracellular matrix interactions (5).

Based on these observations, we hypothesized that the inflammatory milieu might contribute to differential DNA methylation in RA FLS through altered DNMT expression. These studies demonstrate that IL-1 reversibly modulates DNMT levels. DNMT function is also suppressed, and DNA methylation patterns are subsequently modified. The data suggest that the inflammatory milieu might transiently alter FLS methylation and behavior.

Materials and Methods

Fibroblast-like synoviocytes

FLS were isolated from synovial tissues obtained from 14 RA and 12 osteoarthritis (OA) patients at the time of joint replacement as described previously (9). The diagnosis of RA conformed to the American College of Rheumatology 1987 revised criteria (18). The protocol was approved by the University of California, San Diego, Human Subjects Research Protection Program and the Institutional Review Board. Written informed consent was obtained from all patients. This study was approved by the Animal Care and Use Committee at the University of California, San Diego.

Abbreviations used in this article: 5Aza-dC, 5-aza-2'-deoxycytidine; DNMT, DNA methyltransferase; FLS, fibroblast-like synoviocyte; OA, osteoarthritis; poly(LC), polyinosinic-polycytidylic acid; qPCR, quantitative real-time PCR; RA, rheumatoid arthritis.
consent was obtained from participants at the time of sample collection. Synoviocytes were used from passages 4–8, when FLS were a homogenous population with <1% CD11b, <1% phagocytic, and <1% FcR II-positive cells.

Reagents

The Abs and reagents used were as follows: recombinant human TNF and IL-1β (R&D Systems, Minneapolis, MN); LPS, polyinosinic-polycytidylic acid [poly(I:C)], and 5-aza-2′-deoxycytidine (5Aza-dC) were obtained from Sigma-Aldrich (St. Louis, MO). Actinomycin D was purchased from USB Corporation (Cleveland, OH).

Quantitative real-time PCR

mRNA was isolated using RNA Stat 60 (Tel-Test, Friendswood, TX) as described previously (19). cDNA was prepared, and quantitative real-time PCR (qPCR) was performed with TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA) to determine the relative mRNA levels using the GeneAmp 7300 Sequence Detection system (Applied Biosystems). Predesigned specific primers were used to detect DNMT1 (assay number Hs00154749_m1), DNMT3a (Hs01027166_m1), DNMT3b (Hs00171876_m1), CHI3L1 (Hs00609691_m1), COL1A1 (Hs00164004_m1), and MYEF2 (Hs00972066_m1) (Applied Biosystems). Threshold cycle values in each sample were used to calculate the number of cell equivalents in the test samples. The data were normalized to the values for GAPDH (Applied Biosystems) to obtain the relative cell expression (19).

DNMT function

Nuclear extracts were obtained using the nuclear extraction kit (Panomics, Fremont, CA). Extracts from the IL-1β-treated and control cells cultured for 14 d were assayed for DNMT activity using a colorimetric DNMT Activity/Inhibition assay kit (Active Motif, Carlsbad, CA). The reaction was initiated by adding 10 μg nuclear extracts to the unique cytosine-rich DNA substrate–coated ELISA plate and incubated for 2 h at 37°C. Methylated DNA was detected with anti-methyl CpG-binding domain 2b Ab, absorbance was read at 450 nm. Quantification of global DNA methylation assay

Global DNA methylation was assayed using an ELISA-based commercial kit (MDQ1; Imprint Methylated DNA Quantification Kit; Sigma-Aldrich). Two microliters genomic DNA at a concentration of 100 ng/μl was diluted with 28 μl lysis and binding buffers. After incubation with the detection Ab, absorbance was read at 450 nm. Quantification of global DNA methylation was performed by calculating the amount of methylated cytosine in the sample relative using an arbitrary scale. All samples were analyzed in duplicate.

Genomic DNA extraction, bisulfite treatment, and pyrosequencing

Genomic DNA was isolated using the MagMAX DNA Multi-Sample Kit (Applied Biosystems). DNA quality and quantity was determined with a NanoDrop ND-2000 spectrometer (NanoDrop Technologies, Wilmington, DE). Sodium bisulfite modification of genomic DNA was performed with the Epitect bisulfite kit (Qiagen, Valencia, CA). The primers for PCR amplification and sequencing of CHI3L1 (chr1:203156625) were designed using PyroMark assay design SW 2.0. PCR was performed with biotinylated primers to convert the PCR product to ssDNA templates. Pyrosequencing reactions and methylation quantification were performed by the Stanford Protein and Nucleic Acid Facility (http://pan.stanford.edu).

Statistical analysis

Results are expressed as the mean ± SEM. Differences were assessed by one-way and two-way repeated-measures ANOVA, followed by the Bonferroni post hoc test for comparison of multiple groups or Student t test for comparison of two groups. The criterion for significance was set at p values <0.05 after correction.

Results

Basal expression of DNMTs in FLS

DNMT1, DNMT3a, and DNMT3b expression was initially determined in cultured synoviocytes by qPCR. A modest trend toward lower expression was observed in RA FLS, but the differences were not significant (n = 10/group; Fig. 1A). We then examined DNMT protein expression in FLS nuclear extracts by Western blot. Abundant DNMT1 and DNMT3a protein were observed in both RA and OA FLS. Immunoreactive DNMT3b protein was difficult to detect by Western blot analysis using currently available reagents (not shown). As with mRNA levels, there was no significant difference between RA and OA FLS (Fig. 1B).

Decreased DNMT gene expression after cytokine or TLR ligand stimulation

FLS were stimulated with IL-1β, TNF, or TLR ligands LPS and poly(I:C) for 24 h. DNMT expression was then determined by qPCR. DNMT3a mRNA expression was significantly decreased by IL-1β (2 ng/ml), TNF (50 ng/ml), or LPS (1 μg/ml), whereas DNMT1 was significantly decreased by IL-1β and LPS (Fig. 2A). Similar trends were observed for DNMT3b, but the differences were not statistically significant (data not shown).

Regulation of DNMTs by IL-1β

Because IL-1β caused the greatest reduction in DNMT levels, subsequent studies focused on this cytokine. Fig. 3A illustrates that concentrations as low as 1 pg/ml decreased DNMT gene expression. We then examined the kinetics of DNMT suppression in FLS. Cells were stimulated with 2 ng/ml of IL-1β, and DNMT expression was evaluated for up to 24 h. As shown in Fig. 3B, DNMT1 and DNMT3a mRNA levels began to decrease in 8 and 2 h after exposure to IL-1β, respectively. When cells exposed to IL-

![FIGURE 1. Basal gene and protein expression of DNMT in FLS from RA and OA.](http://www.jimmunol.org)
were washed and recultured in medium alone, DNMT expression gradually increased and reached baseline within 14 d (Fig. 3C).

Effect of IL-1 on DNMT mRNA stability

To determine the mechanism of IL-1–mediated suppression of DNMT expression, FLS were cultured with medium or IL-1 for 30 min, and 10 μg/ml of actinomycin D was then added to inhibit mRNA synthesis. DNMT mRNA levels were measured at various time points by qPCR, and β-actin was used as an internal control. The decay rates of DNMTs mRNA were similar in medium or IL-1–stimulated cells (Fig. 3D). Therefore, alterations in mRNA stability do not account for the effect of IL-1, and effects on transcription are more likely responsible.

Decreased DNMT function after IL-1 stimulation

A cytosine methylation functional assay was then performed to determine whether IL-1β suppresses DNA methylation activity in FLS nuclear extracts. Fig. 4A shows that basal DNMT function in RA and OA FLS was similar. When FLS were stimulated with 1 ng/ml of IL-1β, DNMT functional activity was significantly decreased by IL-1β (Fig. 4B).

DNA methylation levels in cultured FLS stimulated with IL-1

To evaluate whether IL-1β might alter global DNA methylation (total methylcytosine) or differential methylation of individual loci, we cultured FLS in the presence of IL-1β (1 ng/ml) for 14 d. An assay of total methylcytosine content of genomic DNA demonstrated that prolonged IL-1β exposure decreased global methylation of FLS (Fig. 5A). In a second experiment to determine...
how long it takes for the effect of IL-1 to reverse, additional FLS lines were cultured with IL-1β for 14 d, washed, and then divided into two groups: 1) cells cultured with medium (IL-1/Med); or 2) cells cultured with fresh IL-1β (IL-1/IL-1). After 14 d, global DNA methylation in IL-1/Med FLS was significantly higher than that in continuous IL-1/IL-1 FLS (Fig. 5B). These data suggest that DNMT suppression by IL-1 maintains long-term hypomethylation in FLS but that the effect is at least partially reversed when cells are removed from the inflammatory milieu.

Potential contribution of IL-1β to the RA methylome signature

It is not known how changes in DNMT expression regulate only specific loci. However, it probably relates to expression of cofactors such as transcription factors in cell types that, under specific conditions, improve accessibility to individual CpG loci. An unbiased genome-wide evaluation of DNA methylation in FLS demonstrated that RA and OA FLS segregate based on DNA methylation (5). To evaluate the contribution of IL-1–induced methylation changes at relevant loci, we measured methylation at the previously identified RA hypomethylated loci of the CH13L1 gene to determine whether IL-1β could reproduce this component of the RA-specific methylation pattern in OA FLS. OA FLS were stimulated with IL-1β for 14 d, and pyrosequencing was performed on the known hypomethylated locus as well as two loci in the same gene that are not differentially methylated in RA. Fig. 6A shows that IL-1 selectively demethylated DNA at the RA hypomethylated locus (chr1:203156625), but had no effect on the other loci (chr1:203156628 and 203156635). As an additional control, LINE1 pyrosequencing was performed on medium and IL-1–stimulated cells. Three selected CpGs of the LINE1 element, which are not differentially methylated in RA, were not affected by IL-1β (not shown).

Effect of IL-1 and a DNMT inhibitor on gene expression

We then evaluated whether the effects of IL-1 on DNA methylation might alter gene expression. Because IL-1 decreases DNMT function, we compared the effect of chronic IL-1 exposure to the DNMT inhibitor 5-Aza-dC on five genes that are hypomethylated in RA FLS (5). Six OA FLS were treated with the demethylating agent 5Aza-dC or IL-1β for 14 d to induce hypomethylation, and qPCR was performed. Gene expression of CH13L1 and COL1A1 was decreased, whereas MYEF2 expression was increased by 5Aza-dC and IL-1β (Fig. 6B). Expression of two additional genes (SYNJ2 and ITGA4) was not changed by either IL-1 or 5Aza-dC (data not shown). These results suggest that long-term exposure to IL-1β mimics the effect of a DNMT inhibitor on differentially methylated genes.

Discussion

Rheumatoid FLS display aggressive behavior and contribute to joint damage (10). Appropriate fibroblast responses to inflammatory cytokines like IL-1 and TNF can account for some of these observations. However, RA cells are imprinted and maintain these features long after they are removed from the synovial environment. For example, RA FLS, unlike OA or normal synoviocytes, adhere to and invade cartilage explants in SCID mice (20). RA FLS are able to grow under anchorage-independent conditions, are less susceptible to contact inhibition, and are resistant to apoptosis (21, 22). RA synoviocytes can also migrate and transfer the invasive phenotype from one joint to another (11). Several mechanisms have been implicated, including abnormal PTEN or sentrin
expression, aberrant sumoylation, or somatic mutations (13, 14, 23–30).

Epigenetic changes, which are heritable alterations in gene expression or phenotype independent of DNA sequences, regulate cell functions relevant to synoviocyte behavior in RA. DNA methylation, histone modification, and microRNAs play a critical role in normal embryonic development and cell transformation in cancer (31). DNA methylation participates by repressing regulatory genes after methylation of the cytosines in CpG motifs. Demethylation is associated with aberrant gene expression and cell transformation (3, 32).

In contrast to cancer, the role of methylation in nononcologic diseases is less well characterized. Global DNA hypomethylation has been described in RA FLS and peripheral mononuclear cells (15, 33). Certain loci in LINE1 element and gene promoters, such as CXCL12, are hypomethylated in cultured FLS (15, 16), whereas other gene promoters like DR3 are hypermethylated (17). Furthermore, our recent genome-wide DNA methylation analysis revealed a unique methylome signature that differentiated RA FLS from OA or normal FLS (5). The differentially methylated loci included numerous genes implicated in the pathogenesis of RA, including signaling molecules, adhesion receptors, and proteases (5).

Because the synovial microenvironment might contribute to imprinting, we evaluated whether cytokines and other mediators in the rheumatoid joint could regulate the machinery responsible for DNA methylation. Three DNA methyltransferases, namely DNMT1, -3a, and -3b, determine DNA methylation patterns in the mammalian genome (34). DNMT3a and DNMT3b mainly regulate de novo methylation whereas DNMT1 maintains methylation of CpG loci, especially during cell proliferation. The DNMTs can potentially contribute to gene repression through methylation-dependent and -independent mechanisms (35).

Studies evaluating the regulation of DNMT gene expression in RA are limited. DNMT1 protein levels were reportedly lower in RA FLS than in OA FLS; the levels in RA FLS remained low in culture and were not suppressed further by TNF, IL-1β, or platelet-derived growth factor (15). In our experiments, basal DNMT expression at the protein and mRNA level was similar in RA and OA FLS. The reasons for the different results are not certain, but are consistent with our observation that RA FLS are differentially methylated but do not exhibit global hypomethylation in a genome-wide scan. It is possible that our culture conditions permit cells to recover more fully from the synovial microenvironment by using later passage cells. The observation that re-exposure to cytokines or TLR ligands suppresses DNMT expression supports this possibility.

Our data also established that proinflammatory cytokines, such as IL-1β, TNF, and the TLR4 ligand LPS, suppress DNMT gene expression in RA and OA FLS. The effect is rapid and associated with diminished DNMT function as determined by the ability to methylate CpG loci in a cell-free system. However, global changes in DNA methylation based on changes in DNMT expression or using DNMT inhibitors are gradual, usually taking up to 2 wk to equilibrate. Therefore, these inflammatory mediators regulate not only DNMT expression as well as their function and global DNA methylation.

DNMT regulation in other cell types has been reported to involve transcriptional activation of the DNMT genes (36, 37), microRNAs, RNA binding proteins, alteration of catalytic activity, half-

FIGURE 6. Effect of IL-1β on DNA methylation pattern and gene expression in FLS. (A) OA FLS were cultured in the presence of IL-1β (1 ng/ml) for 14 d, and genomic DNA was then isolated. After bisulfite conversion, DNA methylation status of CHI3L1 loci (CpG1, chr1:203156625; CpG2, chr1:203156628; and CpG3, chr1:203156635) was determined by pyrosequencing. IL-1 stimulation led to hypomethylation of the RA-associated locus (CpG1), but not the other two loci in the same gene. The composite results are presented as box plots in which the boxes represent the 25th–75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th–90th percentiles. *p < 0.05 versus untreated control. (B) OA FLS were cultured in the presence of 5Aza-dC (5 μM) or IL-1β (1 ng/ml) for 14 d (n = 6 each). Gene expression of CHI3L1, COL1A1, and MYEF2 was determined by qPCR and normalized to GAPDH. 5Aza-dC and IL-1 significantly increased MYEF2, whereas they significantly decreased CHI3L1 and COL1A1. The results are presented as box plots in which the boxes represent the 25th–75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th–90th percentiles. IL-1 and 5Aza-dC were not significantly different. *p < 0.05, **p < 0.01 versus untreated control.
life, or substrate targeting by posttranslational modification (38). Environmental factors or disease states can potentially alter DNMT expression and amplify DNA methylation abnormalities. In our FLS studies, IL-1β did not alter DNMTs mRNA stability, indicating that genes are probably suppressed at the transcriptional level. Further studies defining the relationship between IL-1β and DNMT transcriptional mechanisms are needed to establish how they are regulated in FLS.

One interesting aspect of DNMTs and CpG regulation is that a limited number of DNMT enzymes regulate methylation of only specific loci. This observation is probably due to altered chromosome, promoter, and/or locus accessibility to DNMTs after environmental stress. Histone modification as well as transcription factors that can direct DNMTs to certain regions of the genome are possible mechanisms that explain this effect. For example, Rel/p65 directly recruits DNMT1 to specific tumor suppressor gene loci (39). Thus, a cytokine like IL-1, which activates a discrete set of transcription factors, could have locus-specific effects in addition to global effects.

To explore this possibility, we evaluated how IL-1 affects individual CpG loci in FLS. LINE1 elements, which are not differentially methylated in the RA signature, were not affected by IL-1. A key RA-associated element in CHI3L1 was demethylated by IL-1β in OA FLS, converting this locus to the RA pattern. Other RA-specific loci in CHI3L1 were not affected, possibly because these loci are not accessible to DNMTs after IL-1 stimulation or other inflammatory mediators contribute in a locus-specific manner. Experiments are currently in progress to determine which transcription factors and binding motifs contribute to this selectivity in IL-1-stimulated FLS.

Perhaps more important, the effect of IL-1 does not appear to be permanent, as continuous exposure to IL-1 is required to maintain hypomethylation. Differential methylation of the RA genome in FLS, however, is stable and maintained from passage 3 through at least passage 7 (J.W. Whitaker, R. Shoemaker, D.L. Boyle, J. Hillman, D. Anderson, W. Wang, and G.S. Firestein, manuscript in preparation). Thus, a subset of CpG imprinted in observing in long-term cultured FLS occurs through mechanisms that are independent of transient cytokine effects. Longer-term exposure to IL-1 or combinations of cytokines in vivo is one possible explanation that could lead to permanent changes.

Gene expression in RA FLS in our genome-wide scan correlates with the methylation status of differentially methylated loci (5). Thus, therapeutic interventions that modulate DNMT function currently used in cancer could be useful in RA (40). The potential benefit could potentially be offset by derepression of key regulatory or proinflammatory genes. For example, DNMT inhibitors promote tumor progression in some animal models (41, 42), and previous studies in RA FLS indicate that DNMT inhibition alters gene expression. The mechanism for selectively modifying only certain genes by inhibiting DNMT function is complex and involves a number of gene-targeting cofactors. DNMTs recognize distinct consensus sequences, but these motifs have low specificity (43). DNMTs can directly interact with transcription factors to preserve the methylation status of promoter regions, which might explain why only specific loci are affected by cytokines like IL-1 (43, 44).

The functional relevance of decreased DNMT expression was confirmed by demonstrating that a DNMT inhibitor and IL-1 have similar effects on FLS gene expression. We originally expected that demethylation would increase expression for all genes, as we observed with MYE2F. However, lower expression of CHI3L1 and COL1A1 suggests that IL-1 and 5Aza-dC alter methylation of their transcriptional regulators. The fact that both methods of decreasing DNMT activity had parallel effects supports the concept that IL-1-mediated demethylation alters FLS function.

In conclusion, long-term exposure to the proinflammatory cytokine IL-1 can potentially contribute to the RA FLS DNA methylation pattern through altered DNMT expression. Only certain loci are affected by IL-1, suggesting that other inflammatory mediators are involved or that the cells are irreversibly imprinted through other mechanisms or prior to the onset of arthritis. Furthermore, IL-1–mediated demethylation through DNMT suppression mimicked the effect of a DNMT inhibitor on FLS gene expression. These data suggest that the rheumatoid synovial cytokine milieu can contribute to epigenetic modification of FLS in RA.

Acknowledgments
We thank Josh Hillman for outstanding technical assistance and Dr. Scott Ball and Dr. William Bugbee for providing clinical samples. Dr. Olivier Harismendy and the Clinical and Translational Research Institute BioComputational Center (University of California San Diego School of Medicine) provided assistance designing pyrosequencing experiments.

Disclosures
The authors have no financial conflicts of interest.

References